Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Resverlogix Corp. (T:RVX)

Business Focus: Bio Therapeutic Drugs

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for RVX within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Nov 15, 2021 09:55 ET
Zenith and Newsoara Biopharma Announce Expanded Licensing and Investment
Zenith Capital Corp. (“Zenith” or the “Company”) announced today that Zenith Epigenetics Ltd. (“Zenith Epigenetics”), a wholly-owned subsidiary of Zenith Capital, has entered into a licensing agreement with Newsoara Biopharma Co., Ltd. (“Newsoara”)...
Read full article
Nov 03, 2021 08:00 ET
Resverlogix Enters into a Cooperation Agreement with the Supreme Council of the Arab-African Economy to Support the Development of Apabetalone for COVID-19 Patients
Resverlogix Corp. (“Resverlogix” or the Company”) (TSX: RVX), a world leader in epigenetics or gene regulation, is pleased to announce today that it has entered into a cooperation agreement with the Supreme Council of the Arab-African Economy which...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.24
--
--
Price to Sales - TTM
--
48.06
11.80
Price to Book - most recent quarter
--
4.32
2.88
Price to Cash Flow per share - TTM
21.84
21.84
13.85
Price to Free Cash Flow per share - TTM
--
58.94
36.08
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Nov 15, 2021392,774107,438
Oct 31, 2021285,336-19,402
Oct 15, 2021304,73815,531
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Resverlogix Corp. is a Canada-based clinical biotechnology company that is focused on improving the lives of patients with chronic illnesses. The Company is developing apabetalone (RVX-208), a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that regulates disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. The selective inhibition of apabetalone on BD2 produces a specific set of biological effects for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19. The Company is in the development stage as it is focused on research and development. The Company has not earned any revenue.

See business summary

 

Twitter

Search (past week) for $RVX.CA

  • No tweets found